SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
bjh9042-sup-0001-FigS1.docWord document1239KFig S1. Different modulation of P-ERK1/2 between Sorafenib and Dasatinib in AML cells.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.